What are we expecting in EGFR-mutant NSCLC in 2023?

Learning objective:         

After watching this broadcast, participants should be able to:

• Explore new data on the management of patients with EGFR-mutant NSCLC
• Evaluate emerging therapeutic options for EGFR exon 20 insertion mutations in NSCLC 

Faculty:

• Matthew Krebs (UK)
• Antonio Passaro (Italy)
• Natasha Leighl (Canada)
• Noemi Reguart (Spain)

Claim your CPD credits

The content of the following has been certified by the CPD Certification Service as conforming to continuing professional development principles.

You can claim 1.0 credits for this activity.

Please make a note of the below information to claim your points.

      Name of activity: Janssen Oncology Medical Education Webinar (OME) Post
      ELCC: What are we expecting in EGFR-mutant NSCLC in 2023?

      Certificate number: 41521

      Date of activity: May 2023

      CPD Provider: Sciterion 013096

CPD certification has been approved in principle.